Ameriprise Financial Inc. increased its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 66.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 349,253 shares of the biopharmaceutical company’s stock after buying an additional 139,511 shares during the period. Ameriprise Financial Inc. owned about 0.90% of Ultragenyx Pharmaceutical worth $17,085,000 as of its most recent filing with the SEC.

Other hedge funds also recently added to or reduced their stakes in the company. DIAM Co. Ltd. acquired a new stake in shares of Ultragenyx Pharmaceutical during the second quarter worth approximately $177,000. Springbok Capital Management LLC acquired a new stake in shares of Ultragenyx Pharmaceutical during the first quarter worth approximately $189,000. Creative Planning raised its stake in shares of Ultragenyx Pharmaceutical by 16,700.0% in the second quarter. Creative Planning now owns 4,200 shares of the biopharmaceutical company’s stock worth $205,000 after buying an additional 4,175 shares during the period. Princeton Alpha Management LP acquired a new stake in shares of Ultragenyx Pharmaceutical during the second quarter worth approximately $216,000. Finally, Rothschild Asset Management Inc. acquired a new stake in shares of Ultragenyx Pharmaceutical during the second quarter worth approximately $233,000. Institutional investors own 93.06% of the company’s stock.

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) traded down 0.15% during midday trading on Thursday, reaching $73.68. The company had a trading volume of 283,412 shares. Ultragenyx Pharmaceutical Inc. has a 12-month low of $46.52 and a 12-month high of $117.12. The firm’s market capitalization is $2.91 billion. The company has a 50 day moving average of $67.89 and a 200 day moving average of $63.14.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($1.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.44) by $0.02. During the same period last year, the company posted ($0.83) earnings per share. Analysts anticipate that Ultragenyx Pharmaceutical Inc. will post ($5.96) EPS for the current year.

A number of brokerages have commented on RARE. Jefferies Group set a $109.00 price target on shares of Ultragenyx Pharmaceutical and gave the company a “buy” rating in a research note on Sunday. Wedbush restated an “outperform” rating and set a $92.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Monday. Leerink Swann restated an “outperform” rating and set a $94.00 price target (up previously from $85.00) on shares of Ultragenyx Pharmaceutical in a research note on Tuesday. Canaccord Genuity set a $120.00 price target on shares of Ultragenyx Pharmaceutical and gave the company a “buy” rating in a research note on Tuesday. Finally, Morgan Stanley restated a “hold” rating on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, June 8th. Three analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $97.89.

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 20,000 shares of the stock in a transaction on Monday, August 15th. The stock was sold at an average price of $67.61, for a total value of $1,352,200.00. Following the completion of the transaction, the chief executive officer now owns 493,244 shares in the company, valued at $33,348,226.84. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Sunil Agarwal sold 649 shares of the stock in a transaction on Thursday, July 21st. The stock was sold at an average price of $52.68, for a total value of $34,189.32. The disclosure for this sale can be found here. 10.10% of the stock is owned by company insiders.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment.

5 Day Chart for NASDAQ:RARE

Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.